Kadoba, Keiichiro
Watanabe, Ryu
Iwasaki, Takeshi
Nakajima, Toshiki
Kitagori, Koji
Akizuki, Shuji
Murakami, Kosaku
Nakashima, Ran
Hashimoto, Motomu
Tanaka, Masao
Ohmura, Koichiro
Morinobu, Akio
Terao, Chikashi
Yoshifuji, Hajime
Funding for this research was provided by:
JSPS KAKENHI (20K17418)
The Cardiovascular Research Fund, Tokyo, Japan
Article History
Received: 25 February 2021
Accepted: 21 June 2021
First Online: 1 July 2021
Competing interests
: The Department of Advanced Medicine for Rheumatic Diseases is supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan and five pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd, UCB Japan Co. Ltd, AYUMI Pharmaceutical Co., and Asahi Kasei Pharma Corp.). The above-mentioned pharmaceutical companies were not involved in the study design, data collection and analysis, manuscript writing, and manuscript submission. RW received speaker fees from Mitsubishi Tanabe Pharma, Pfizer, Sanofi, AbbVie, Asahi Kasei, Eisai, Eli Lilly, Bristol-Myers Squibb, and Janssen. KK received research grants from GSK. KMurakami received speaking fees and/or consulting fees from Eisai Co. Ltd, Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma Corporation, UCB Japan Co. Ltd, Daiichi Sankyo Co. Ltd., and Astellas Pharma Inc. MH received a research grant and/or speaker fees from Bristol-Myers, Eisai, Ely Lilly, Mitsubishi Tanabe Pharma. MT received research grants and/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, Pfizer Inc., UCB Japan Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., and Taisho Pharma Co., Ltd. KO received research grants and/or speaker fees from Abbvie, Actelion, Asahikasei Pharma, Astellas, AYUMI, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Janssen, JB, Mitsubishi Tanabe, Nippon Kayaku, Nippon Shinyaku, Novartis, Sanofi, and Takeda. AM received speaking fees and/or research grants from Chugai Pharmaceutical Co. Ltd. HY received lecture fees from Chugai and has been on the advisory board for a clinical trial conducted by Janssen. All other authors have declared no conflicts of interest.